[
  {
    "ts": "2025-07-28T14:36:00+00:00",
    "headline": "CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?",
    "summary": "CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.",
    "url": "https://finance.yahoo.com/news/crispr-therapeutics-report-q2-earnings-143600748.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a29af598-a731-3b4d-b7c1-9e0d84054aee",
      "content": {
        "id": "a29af598-a731-3b4d-b7c1-9e0d84054aee",
        "contentType": "STORY",
        "title": "CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?",
        "description": "",
        "summary": "CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.",
        "pubDate": "2025-07-28T14:36:00Z",
        "displayTime": "2025-07-28T14:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w5T7o1LHfvUowVKdWOi4Rg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3L0ANckA9Qf5lXTiNAgdWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-report-q2-earnings-143600748.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-report-q2-earnings-143600748.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-28T14:00:17+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-reports-next-140017288.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bd0a982b-9a81-3a0e-acec-e5fd1d1da08a",
      "content": {
        "id": "bd0a982b-9a81-3a0e-acec-e5fd1d1da08a",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth",
        "description": "",
        "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2025-07-28T14:00:17Z",
        "displayTime": "2025-07-28T14:00:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
          "originalWidth": 900,
          "originalHeight": 598,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2yFNHFE.NEelN3EcxccP6Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177.cf.webp",
              "width": 900,
              "height": 598,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tL0vRMsfrFLR6L27GP3atA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-reports-next-140017288.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-reports-next-140017288.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-28T11:15:00+00:00",
    "headline": "The 3 Things That Matter for Vertex Pharmaceuticals Now",
    "summary": "Some of these developments could improve the company's prospects.",
    "url": "https://www.fool.com/investing/2025/07/28/the-3-things-that-matter-for-vertex-pharmaceutical/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7c94db1b-5098-35d7-b9c6-58cbd446b6a9",
      "content": {
        "id": "7c94db1b-5098-35d7-b9c6-58cbd446b6a9",
        "contentType": "STORY",
        "title": "The 3 Things That Matter for Vertex Pharmaceuticals Now",
        "description": "",
        "summary": "Some of these developments could improve the company's prospects.",
        "pubDate": "2025-07-28T11:15:00Z",
        "displayTime": "2025-07-28T11:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d18091d425f9eeb6ed39fd98b292cbe5",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "Pharmacist talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8HPx3dvLjFqwkP77X34BLA--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d18091d425f9eeb6ed39fd98b292cbe5.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bnBb9L3il_14JoheMpFAVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d18091d425f9eeb6ed39fd98b292cbe5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/07/28/the-3-things-that-matter-for-vertex-pharmaceutical/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-things-matter-vertex-pharmaceuticals-111500457.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-28T04:04:39+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings?",
    "summary": "Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the last six months while the S&P 500 has gained 5.4%.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-buy-sell-040439475.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "3b04479b-cb70-3c00-b201-346ff23a66d0",
      "content": {
        "id": "3b04479b-cb70-3c00-b201-346ff23a66d0",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings?",
        "description": "",
        "summary": "Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the last six months while the S&P 500 has gained 5.4%.",
        "pubDate": "2025-07-28T04:04:39Z",
        "displayTime": "2025-07-28T04:04:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-buy-sell-040439475.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-buy-sell-040439475.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]